Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails – such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA ...
Aug 28, 2012
0
0